ClinicalTrials.gg

Program

THRV-1268

A development code.

Its studies are mostly in Long QT Syndrome · Heart Failure · Atrial Fibrillation, led by Thryv Therapeutics.

Furthest: phase 3, since Dec 2, 20253 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Thryv Therapeutics31 open or runningphase 3since Dec 2, 2025Jul 11, 2024Jun 30, 2027phase 3 · NCT07277582

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2024First study: phase 1 study in Atrial FibrillationFirst studyNCT06507839 · 56 enrolled · Canada
  2. Sep 15, 2025Phase 1 study in Heart FailureNCT07186946 · 16 enrolled · United States
  3. Dec 2, 2025Phase 3 study in Long QT SyndromePhase 3 reachedNCT07277582 · 84 planned · United States

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Long QT SyndromeNCT07277582

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07277582Long QT Syndrome · United States3RecruitingJun 30, 202784
NCT07186946Heart Failure · United States1CompletedOct 20, 202516
NCT06507839Atrial Fibrillation · Canada1CompletedNov 1, 202456

How it is read

Names in the registry

  • “THRV-1268”, 4 entries

Codes read as this program: THRV1268.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.